Respiratory Syncytial Virus Therapeutics Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2029
Overview
Global Respiratory Syncytial Virus Therapeutics Market is expected to grow at a CAGR of 31.20% during the forecast period to reach US$ 7001.1 Mn. by 2029.
Respiratory Syncytial Virus Therapeutics Market Drivers and Restrains:
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory infections such as bronchiolitis and pneumonia. The increasing cases of RSV infections are fueling the demand for rapid diagnostic methods globally. Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are impel the respiratory syncytial virus (RSV) therapeutics market from in the near future.
To know about the Research Methodology:- Request Free Sample Report
The major driving factors of the respiratory syncytial virus therapeutics market such as increasing incidence rate of respiratory infections, growing demand for in-vitro diagnostics, and increasing demand facilities like care taken during treatment. RSV is a common cause of bronchiolitis and pneumonia in babies. RSV is spread from respiratory emissions through close contact with infected persons. The unavailability of approved drug or vaccine has been made accessible to treat or prevent RSV infection till date. Patients are treated only by administering prophylaxis drugs. Manufacturers are focusing on the development of new drugs and vaccines with better efficacy, which is likely to fuel the respiratory syncytial virus (RSV) therapeutics market in the upcoming period.
The current shortage of specific treatment options, the development of vaccines for RSV in the future, the high price of prophylaxis drugs, lack of efficacy of the drugs and resistance against RSV infection are factors that are likely to hamper this segment. There are several unmet needs in market and biologics, which provides lucrative opportunities for existing players and new entrants in the global market.
Segmentation Analysis:
Based on the causative virus, the market has been segmented into respiratory syncytial viruses (RSV) infectious, influenza virus’s infectious, parainfluenza viruses infectious, adenoviruses infectious, rhinoviruses infectious. The Respiratory syncytial virus infectious segment accounts for a major share of the respiratory virus infection drugs market in 2022. The RSV is most common type of respiratory virus infection, while parainfluenza, adenoviruses, and rhinoviruses fall into the less common forms. According to the World Health Organization, almost xx million people are infected and nearly xx% deaths caused because of respiratory syncytial virus, yearly.
Based on the distribution channel, the market has been segmented into hospital pharmacies, drug stores, retail pharmacies, clinics. The hospital pharmacies segment is expected to grow at CAGR of xx% during the forecast period. Emphasis on establishing hospitals as primary care providers. Several state-of-art hospital chains globally, owing to the rising government funds, and improving availability to medicines at reasonable prices are help to the hospital pharmacy segment to retain its strong market position during the forecast period.
Regional Analysis:
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the prominent share of market in 2022 owing to the high level of research activity in the U.S., high awareness and easily available diagnostic tests. Furthermore, presence of several key players has led to increased investment in research and development of anti RSV drugs. Therefore, presence of these players are projected to propel the syncytial virus (RSV) therapeutics market in North America at a rapid pace during the forecast period. According to the U.S., Department of Health & Human Services, nearly xx% of the children infected with RSV were under two-years of the age, worldwide.
Asia Pacific is expected to grow at the largest CAGR of xx% during the forecast period. Lack of appropriate population-based studies in emerging countries could challenge the valuation of respiratory-related virus infections. Pharmaceutical research and development spending in developing markets such as China and India is rising, which is driving the growth of the Asia Pacific respiratory syncytial virus (RSV) therapeutics market.
Respiratory Syncytial Virus Therapeutics Market Competitive landscape
Major Key players operating in this market are AstraZeneca, AbbVie, Ablynx NV, ADMA Biologics, Alnylam Pharmaceuticals, and Ark Biosciences. Manufacturers in the respiratory syncytial virus therapeutics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present comprehensive analysis of market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding global market dynamics, structure by analyzing the market segments, and project the market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the market make the report investor’s guide.
Respiratory Syncytial Virus Therapeutics Market Scope: Inquire before buying
| Global Respiratory Syncytial Virus Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US$ 1046 Mn. |
| Forecast Period 2023 to 2029 CAGR: | 31.2% | Market Size in 2029: | US$ 7001.1 Mn. |
| Segments Covered: | by Type of Causative Virus | Respiratory syncytial viruses (RSV) infectious Influenza viruses infectious Parainfluenza viruses infectious Adenoviruses infectious Rhinoviruses infectious |
|
| by Distribution Channel | Hospital pharmacies Drug stores Retail pharmacies Clinics |
||
Respiratory Syncytial Virus Therapeutics Market, by Region:
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Respiratory Syncytial Virus Therapeutics Market, Key Players:
1. AstraZeneca
2. AbbVie
3. Ablynx NV
4. ADMA Biologics
5. Alnylam Pharmaceuticals
6. Ark Biosciences
7. ImmunoVaccine Technologies
8. Aviragen Therapeutics
9. Boehringer Ingelheim
10. Bavarian Nordic
11. Gilead Sciences
12. Johnson & Johnson
13. Kyowa Hakko Kirin
14. Mymetics Corporation
15. GlaxoSmithKline plc.
16. Teva Pharmaceutical
17. Vaxart
18. Dickinson and Company
19. Novartis Diagnostics
20. Abbott Laboratories
21. Ortho Clinical Diagnostics
22. Thermo Fisher Scientific Inc.
23. Bio-Rad Laboratories Inc.
24. Hoffmann La Roche Limited
Frequently Asked Questions:
1. Which region has the largest share in Global Respiratory Syncytial Virus Therapeutics Market?
Ans: North America region holds the highest share in 2022.
2. What is the growth rate of Global Respiratory Syncytial Virus Therapeutics Market?
Ans: The Global Respiratory Syncytial Virus Therapeutics Market is growing at a CAGR of 31.2% during forecasting period 2023-2029.
3. What is scope of the Global Respiratory Syncytial Virus Therapeutics market report?
Ans: Global Respiratory Syncytial Virus Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Respiratory Syncytial Virus Therapeutics market?
Ans: The important key players in the Global Respiratory Syncytial Virus Therapeutics Market are – AstraZeneca, AbbVie, Ablynx NV, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, ImmunoVaccine Technologies, Aviragen Therapeutics, Boehringer Ingelheim, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, Kyowa Hakko Kirin, Mymetics Corporation, GlaxoSmithKline plc., and Teva Pharmaceutical.
5. What is the study period of this market?
Ans: The Global Respiratory Syncytial Virus Therapeutics Market is studied from 2022 to 2029.